US Stock Market Closed

Dashboard

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

S

Analyst Opinion

B

Leverage & Liquidity

S

Fundamental Variables

H

Rating Performance

FV Performance

About

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

CEO

Emma N. Walmsley

Employees

-

Industry

-

Sector

-

Headquarters

Middlesex

Exchange

New York Stock Exchange

Website

http://gsk.com

Summary Stats

Market Cap

71.9B

Revenue

30.4B

Net Income

14.2B

EPS

$6.87

Price-to-Earnings

5.11

Price-to-Book

7.08

Debt-to-Equity

5.59

News

Analyst Ratings

Price targets projected by 19 analysts

High

$60.00

Average

$46.02

Low

$33.00

Ratings calculated by 24 analysts

Buy

13

Hold

10

Sell

1

Last Dividend

Amount

$0.32

Dividend Date

Frequency

quarterly

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q4 2022

Last Earnings

Above by $0.11

Actual

$0.61 +22.0%

Consensus

0.5

Report Date

Year Ago

0.69

Year Ago Change %

Down 11%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites